|
1
|
Fraser M, Berlin A, Bristow RG and van der
Kwast T: Genomic, pathological, and clinical heterogeneity as
drivers of personalized medicine in prostate cancer. Urol Oncol.
33:85–94. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cooperberg MR, Broering JM, Litwin MS,
Lubeck DP, Mehta SS, Henning JM and Carroll PR;
CaPSUREInvestigators, : The contemporary management of prostate
cancer in the United States: Lessons from the cancer of the
prostate strategic urologic research endeavor (CapSURE), a national
disease registry. J Urol. 171:1393–1401. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dall'Era MA, Cooperberg MR, Chan JM,
Davies BJ, Albertsen PC, Klotz LH, Warlick CA, Holmberg L, Bailey
DE Jr, Wallace ME, et al: Active surveillance for early-stage
prostate cancer: Review of the current literature. Cancer.
112:1650–1659. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Capitanio U, Briganti A, Gallina A, Suardi
N, Karakiewicz PI, Montorsi F and Scattoni V: Predictive models
before and after radical prostatectomy. Prostate. 70:1371–1378.
2010.PubMed/NCBI
|
|
5
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jansson MD and Lund AH: MicroRNA and
cancer. Mol Oncol. 6:590–610. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cho WC: MicroRNAs: Potential biomarkers
for cancer diagnosis, prognosis and targets for therapy. Int J
Biochem Cell Biol. 42:1273–1281. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kim WT and Kim WJ: MicroRNAs in prostate
cancer. Prostate Int. 1:3–9. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Volinia S, Calin GA, Liu CG, Ambs S,
Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et
al: A microRNA expression signature of human solid tumors defines
cancer gene targets. Proc Natl Acad Sci USA. 103:pp. 2257–2261.
2006; View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ambs S, Prueitt RL, Yi M, Hudson RS, Howe
TM, Petrocca F, Wallace TA, Liu CG, Volinia S, Calin GA, et al:
Genomic profiling of microRNA and messenger RNA reveals deregulated
microRNA expression in prostate cancer. Cancer Res. 68:6162–6170.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Porkka KP, Pfeiffer MJ, Waltering KK,
Vessella RL, Tammela TL and Visakorpi T: MicroRNA expression
profiling in prostate cancer. Cancer Res. 67:6130–6135. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ozen M, Creighton CJ, Ozdemir M and
Ittmann M: Widespread deregulation of microRNA expression in human
prostate cancer. Oncogene. 27:1788–1793. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fabris L, Ceder Y, Chinnaiyan AM, Jenster
GW, Sorensen KD, Tomlins S, Visakorpi T and Calin GA: The potential
of MicroRNAs as prostate cancer biomarkers. Eur Urol. 70:312–322.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xu T, Zhu Y, Xiong Y, Ge YY, Yun JP and
Zhuang SM: MicroRNA-195 suppresses tumorigenicity and regulates
G1/S transition of human hepatocellular carcinoma cells.
Hepatology. 50:113–121. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bhattacharya A, Schmitz U, Wolkenhauer O,
Schönherr M, Raatz Y and Kunz M: Regulation of cell cycle
checkpoint kinase WEE1 by miR-195 in malignant melanoma. Oncogene.
32:3175–3183. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li D, Zhao Y, Liu C, Chen X, Qi Y, Jiang
Y, Zou C, Zhang X, Liu S, Wang X, et al: Analysis of MiR-195 and
MiR-497 expression, regulation and role in breast cancer. Clin
Cancer Res. 17:1722–1730. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ding J, Huang S, Wang Y, Tian Q, Zha R,
Shi H, Wang Q, Ge C, Chen T, Zhao Y, et al: Genome-wide screening
reveals that miR-195 targets the TNF-α/NF-κB pathway by
down-regulating IκB kinase alpha and TAB3 in hepatocellular
carcinoma. Hepatology. 58:654–666. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Soon PS, Tacon LJ, Gill AJ, Bambach CP,
Sywak MS, Campbell PR, Yeh MW, Wong SG, Clifton-Bligh RJ, Robinson
BG and Sidhu SB: miR-195 and miR-483-5p identified as predictors of
poor prognosis in adrenocortical cancer. Clin Cancer Res.
15:7684–7692. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jia LF, Wei SB, Gong K, Gan YH and Yu GY:
Prognostic implications of micoRNA miR-195 expression in human
tongue squamous cell carcinoma. PLoS One. 8:e566342013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fu MG, Li S, Yu TT, Qian LJ, Cao RS, Zhu
H, Xiao B, Jiao CH, Tang NN, Ma JJ, et al: Differential expression
of miR-195 in esophageal squamous cell carcinoma and miR-195
expression inhibits tumor cell proliferation and invasion by
targeting of Cdc42. FEBS Lett. 587:3471–3479. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cai C, Chen QB, Han ZD, Zhang YQ, He HC,
Chen JH, Chen YR, Yang SB, Wu YD, Zeng YR, et al: miR-195 inhibits
tumor progression by targeting RPS6KB1 in human prostate cancer.
Clin Cancer Res. 21:4922–4934. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Taylor BS, Schultz N, Hieronymus H,
Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva
B, et al: Integrative genomic profiling of human prostate cancer.
Cancer Cell. 18:11–22. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Maragkakis M, Alexiou P, Papadopoulos GL,
Reczko M, Dalamagas T, Giannopoulos G, Goumas G, Koukis E, Kourtis
K, Simossis VA, et al: Accurate microRNA target prediction
correlates with protein repression levels. BMC Bioinformatics.
10:2952009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lin ZY, Huang YQ, Zhang YQ, Han ZD, He HC,
Ling XH, Fu X, Dai QS, Cai C, Chen JH, et al: MicroRNA-224 inhibits
progression of human prostate cancer by downregulating TRIB1. Int J
Cancer. 135:541–550. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ong SE, Blagoev B, Kratchmarova I,
Kristensen DB, Steen H, Pandey A and Mann M: Stable isotope
labeling by amino acids in cell culture, SILAC, as a simple and
accurate approach to expression proteomics. Mol Cell Proteomics.
1:376–386. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Iorio MV and Croce CM: microRNA
involvement in human cancer. Carcinogenesis. 33:1126–1133. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bolton EM, Tuzova AV, Walsh AL, Lynch T
and Perry AS: Noncoding RNAs in prostate cancer: The long and the
short of it. Clin Cancer Res. 20:35–43. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu C, Guan H, Wang Y, Chen M, Xu B, Zhang
L, Lu K, Tao T, Zhang X and Huang Y: miR-195 inhibits EMT by
targeting FGF2 in prostate cancer cells. PLoS One. 10:e01440732015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wu J, Ji A, Wang X, Zhu Y, Yu Y, Lin Y,
Liu Y, Li S, Liang Z, Xu X, et al: MicroRNA-195-5p, a new regulator
of Fra-1, suppresses the migration and invasion of prostate cancer
cells. J Transl Med. 13:2892015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Guo J, Wang M and Liu X: MicroRNA-195
suppresses tumor cell proliferation and metastasis by directly
targeting BCOX1 in prostate carcinoma. J Exp Clin Cancer Res.
34:912015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang C, Zhang Y, Li Y, Zhu H, Wang Y, Cai
W, Zhu J, Ozaki T and Bu Y: PRR11 regulates late-S to G2/M phase
progression and induces premature chromatin condensation (PCC).
Biochem Biophys Res Commun. 458:501–508. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ji Y, Xie M, Lan H, Zhang Y, Long Y, Weng
H, Li D, Cai W, Zhu H, Niu Y, et al: PRR11 is a novel gene
implicated in cell cycle progression and lung cancer. Int J Biochem
Cell Biol. 45:645–656. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Larance M, Ahmad Y, Kirkwood KJ, Ly T and
Lamond AI: Global subcellular characterization of protein
degradation using quantitative proteomics. Mol Cell Proteomics.
12:638–650. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chen Y, Cha Z, Fang W, Qian B, Yu W, Li W,
Yu G and Gao Y: The prognostic potential and oncogenic effects of
PRR11 expression in hilar cholangiocarcinoma. Oncotarget.
6:20419–20433. 2015.PubMed/NCBI
|
|
35
|
Song Z, Liu W, Xiao Y, Zhang M, Luo Y,
Yuan W, Xu Y, Yu G and Hu Y: PRR11 is a prognostic marker and
potential oncogene in patients with gastric cancer. PLoS One.
10:e01289432015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhou F, Liu H, Zhang X, Shen Y, Zheng D,
Zhang A, Lai Y and Li H: Proline-rich protein 11 regulates
epithelial-to-mesenchymal transition to promote breast cancer cell
invasion. Int J Clin Exp Pathol. 7:8692–8699. 2014.PubMed/NCBI
|
